# Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes

> **NCT00380653** · PHASE1 · COMPLETED · sponsor: **Cyclacel Pharmaceuticals, Inc.** · enrollment: 47 (actual)

## Conditions studied

- Leukemias
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** sapacitabine

## Key facts

- **NCT ID:** NCT00380653
- **Lead sponsor:** Cyclacel Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2008-11
- **Final completion:** 2009-06
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2021-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00380653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00380653, "Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00380653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*